PharmaShots

JUNE 13, 2023

Eisai's and Merck Announces EU's Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular Carcinoma Published: 23 Aug,2018 | Tags: Eisai, Merck, Approval, Lenvima, HCC, 2. Pfizer to co-promote Exact Sciences Cologuard Published: 22 Aug,2018 | Tags: Exact, Pfizer, Agreement, Promote, Cologuard 7.

Labelling 52

Labelling FDA 52

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 64

FDA Immunization 64

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

The Checkup by Singlecare

SEPTEMBER 7, 2023

Compare Mounjaro alternatives | Other GLP-1 receptor agonists | Oral biguanides | SGLT2 inhibitors | DPP4 inhibitors | GLP-1 receptor agonists for weight loss | Natural alternatives | How to switch meds Diet and exercise alone aren’t enough to control Type 2 diabetes. Fortunately, drug therapy for diabetes has come a long way.

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

The Checkup by Singlecare

NOVEMBER 2, 2023

The study assessed the effectiveness of combining Saxenda (liraglutide 3 mg) with intensive behavioral therapy (IBT) for obesity. The IBT for all participants consisted of regular behavioral counseling sessions, a restricted-calorie diet, and exercise, building up from 100 to 250 minutes per week. in the placebo group.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

The Checkup by Singlecare

MARCH 21, 2023

Opioids should not be used as first-line therapy for short-term or chronic pain —with the exception being in end-of-life or palliative care, during active cancer treatment, and with sickle cell disease. Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag.

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

The Checkup by Singlecare

MAY 8, 2023

Non-drug measures, such as exercise, ice, heat, massage, and weight loss, should be emphasized in managing any type of pain, as appropriate. Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag. fibromyalgia ).

Controlled Substances 52

Controlled Substances Dosage Labelling FDA 52